ased in Belgium and established in 1996, Coris BioConcept is a middle-sized company (SME) specialized in developing, manufacturing and marketing rapid diagnostic kits for the detection of human respiratory, gastro-enteric and blood-borne pathogens (bacteria, viruses and parasites) and for the detection of antibiotic resistance markers (RESIST range). These tests are based on the lateral flow immunochromatography technology with colloidal gold particles or latex microspheres. These rapid tests are extensively used in microbiology laboratories worldwide.
Coris BioConcept was at the forefront to tackle COVID-19 by developing a rapid ICT assay for SARS-CoV-2 antigen detection. Recently, a serological single test has also been developed and
validated for the detection and discrimination of antibodies against NP and RBD.
Coris BioConcept provides services for custom tests development and contract manufacturing. The company is present in more than 80 countries in Europe, Asia, South America, Africa and Oceania.
Coris BioConcept is continually involved in collaborative projects with Belgian and European Research Institutes, laboratories and companies for the development of breaking new solutions.